C4-Substituted Tryptamine Salts for Targeted, Longer-Acting Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing tryptamine-based drugs exhibit suboptimal pharmacodynamic and pharmacokinetic characteristics, leading to inadequate targeting of desired receptors, broad bodily distribution, and frequent dosing requirements, which can result in undesirable side effects and reduced patient compliance.
Innovation Solution
Development of C4-substituted tryptamine derivative salts, including C4-carboxylic acid- and C4-carbonothioate-substituted tryptamine derivatives, formulated as pharmaceutical compounds with specific counter-balancing anions to enhance receptor targeting and prolong drug action, thereby improving pharmacological effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If tryptamine-based drugs are administered to achieve therapeutic effects, then the drug can interact with receptors to produce pharmacological effects, but the drug exhibits broad bodily distribution and suboptimal receptor targeting
Solution Approach 1:
The patent applies local quality by introducing specific substituents at the C4 position of the tryptamine core structure. These localized chemical modifications (carboxylic acid, carbonothioate groups) create specific molecular characteristics that enhance binding affinity and selectivity for target receptors, thereby improving receptor targeting specificity while reducing broad bodily distribution.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters including substituent types (carboxylic acid vs. carbonothioate), substitution positions (C4), and salt forms. These parameter modifications optimize the drug's pharmacokinetic and pharmacodynamic properties to achieve better receptor targeting and reduced off-target effects.
2Reliability
If tryptamine-based drugs are administered to achieve desired therapeutic effects, then the drug can interact with target receptors, but the drug requires frequent dosing due to suboptimal pharmacokinetic characteristics
Solution Approach 1:
The patent utilizes parameter changes by exploring different salt forms and chemical derivatives to optimize pharmacokinetic parameters. These modifications aim to extend the duration of drug action, allowing for less frequent dosing while maintaining therapeutic efficacy. The systematic variation of chemical parameters helps achieve sustained receptor engagement.
3Reliability
If tryptamine-based drugs are administered to treat mental health conditions, then the drug can produce therapeutic effects, but undesirable side effects occur due to suboptimal pharmacodynamic characteristics
Solution Approach 1:
The patent applies local quality by introducing specific functional groups at the C4 position to enhance selectivity for target receptors involved in mental health conditions. This localized modification improves therapeutic efficacy while minimizing interactions with non-target receptors that cause side effects, thereby improving the therapeutic index.
4Reliability
If tryptamine-based drugs are administered to achieve adequate receptor concentration, then the drug can produce desired pharmacological effects, but the drug concentration at the receptor remains suboptimal
Solution Approach 1:
The patent employs parameter changes by optimizing the chemical structure through C4 substitution and salt form selection to improve drug solubility, stability, and membrane permeability. These parameter optimizations enhance the drug's ability to reach and maintain adequate concentrations at the target receptor site, ensuring effective pharmacological activity.
Data Source
AI summary
Disclosed are novel salts of C4-carboxylic acid-substituted and C4-carbonothioate-substituted tryptamine derivative compounds and pharmaceutical and recreational drug formulations containing the same. The pharmaceutical formulations may be used to treat brain neurological disorders.